A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...
What Happened? Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 2.4% in the afternoon session after Canaccord Genuity upgraded the company's...
Progyny’s first quarter was met with a positive market response, driven by revenue and non-GAAP profit that exceeded Wall Street expectations. Management hig...
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Progyny (NASDAQ:PGNY) reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and profitability exceeding expectations amid continued investments in its platform and member experience.
On the company’s earnings call, CEO Pete Anevski said first-qua
What Happened? Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 17.5% in the afternoon session after the company reported first-quarter 2026...
Fertility benefits company Progyny (NASDAQ:PGNY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 1.4% year on year to $328.5...
Fertility benefits company Progyny (NASDAQ:PGNY) will be reporting results this Thursday after the bell. Here’s what to expect. Progyny beat analysts’ revenu...
Although the S&P 500 is down 2.1% over the past six months, Progyny’s stock price has fallen further to $17.17, losing shareholders 16.6% of their capital. T...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Shares of fertility benefits company Progyny (NASDAQ:PGNY)
fell 22% in the afternoon session after it issued a weak financial outlook for 2026 that overshadowed its fourth-quarter results.
Fertility benefits company Progyny (NASDAQ:PGNY) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.7% year on year to $318.4 million. On the other hand, next quarter’s revenue guidance of $325.5 million was less impressive, coming in 5.1% below analysts’ estimates. Its non-GAAP profit of $0.48 per share was 19.9% above analysts’ consensus estimates.
